Biomerica (NASDAQ:BMRA) Posts Earnings Results

Biomerica (NASDAQ:BMRA) posted its quarterly earnings data on Tuesday. The company reported ($0.08) EPS for the quarter, reports. The company had revenue of $1.81 million for the quarter. Biomerica had a negative return on equity of 69.21% and a negative net margin of 110.44%.

Biomerica Stock Performance

Shares of BMRA opened at $0.34 on Thursday. The stock has a 50-day moving average of $0.35 and a two-hundred day moving average of $0.48. The stock has a market cap of $5.72 million, a P/E ratio of -0.92 and a beta of -1.11. Biomerica has a one year low of $0.24 and a one year high of $2.13.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Russell Investments Group Ltd. increased its holdings in Biomerica by 11.8% in the 1st quarter. Russell Investments Group Ltd. now owns 225,435 shares of the company’s stock worth $188,000 after buying an additional 23,872 shares during the period. Perritt Capital Management Inc acquired a new stake in shares of Biomerica in the second quarter worth $31,000. Finally, Fore Capital LLC increased its stake in shares of Biomerica by 72.1% in the first quarter. Fore Capital LLC now owns 59,680 shares of the company’s stock worth $50,000 after acquiring an additional 25,000 shares during the period. 22.28% of the stock is currently owned by hedge funds and other institutional investors.

About Biomerica

Biomerica, Inc, a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations.